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less likely to have a response to the drug or sur-
vive to hospital discharge. We agree that earlier 
use of antiarrhythmic drugs provides a greater 
potential for clinical benefit that may be lost if 
the drugs are administered late. For example, in 
prespecified subgroup analyses in our trial, we 
observed no effect (neither benefit nor harm) 
from active drug among 839 patients with un-
witnessed out-of-hospital cardiac arrest; these pa-
tients typically have a more prolonged duration 
between arrest and treatment than do patients 
with witnessed out-of-hospital arrest. Conversely, 
among 1934 patients with out-of-hospital cardiac 
arrest that was witnessed by a bystander, the rate 
of survival to hospital discharge was significantly 
increased by an absolute margin of 5 percentage 
points with active drug as compared with placebo 
(P≤0.04). Furthermore, among 154 patients in 
whom out-of-hospital cardiac arrest was witnessed 
by EMS and cardiopulmonary resuscitation, shock, 
and the study drug were administered soon after 
the arrest, the absolute increase in survival to 
hospital discharge with amiodarone as compared 
with placebo was 21.9 percentage points (P<0.01). 
These findings suggest a pronounced drug effect 
in patients who are in an earlier, more responsive 
stage of cardiac arrest. The overall results of the 
trial are arguably best interpreted in the context 
of this group of patients.4
Much remains to be learned about the effec-
tiveness of pharmacologic therapies in patients 
with out-of-hospital cardiac arrest. We think 
that our trial has advanced the knowledge and 
understanding of these therapies and has pro-
vided reasons to be optimistic about their use in 
shock-refractory cardiac arrest.
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Colorectal Cancer on the Decline
To the Editor: In their Perspective article, Welch 
and Robertson (April 28 issue)1 provide evidence 
from the Surveillance, Epidemiology, and End Re-
sults Program that the population 50 years of age 
or older has had a steady decline in colorectal-
cancer incidence that is unlikely to be explained 
merely by screening. Surprisingly, according to 
the same data source, during the period when 
incidence rates were declining in this population, 
they have steadily increased in the population 
younger than 50 years of age.2 The incidence of 
colorectal cancer among younger people is also 
increasing in at least one other country.3 Obesity 
or other lifestyle factors might be an explanation 
for the age-specific dissimilarity in time trends, 
especially if these factors have a greater effect on 
younger people than on older people.
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To the Editor: Welch and Robertson suggest 
that screening cannot explain the entire decline 
in colorectal-cancer incidence and mortality (i.e., 
overall decreases of 40% and 50%, respectively, 
among adults in the United States) in the period 
from 1975 to 2012 and that other factors (e.g., 
risk factors such as diet, lifestyle, and drugs) 
must be involved. Surprisingly, the authors did 
not cite the respective proportions of the decline 
that were attributable to screening as opposed to 
those other factors, as analyzed in the “Annual 
Report to the Nation on the Status of Cancer, 
1975–2006,” which features colorectal-cancer 
trends and the effect of risk factors, screening, 
and treatment.1 Using the well-validated Micro-
simulation Screening Analysis (MISCAN)–Colon 
model,2 the authors of that report concluded that 
53% of the overall observed decline in colorectal-
cancer–related mortality could be explained by 
screening, as compared with 35% that could be 
explained by changes in risk factors and 12% 
by treatment.1 The same MISCAN-Colon model 
allowed analysts to suggest that differences in 
screening accounted for 42% and 19% of the ob-
served disparities in colorectal-cancer incidence 
and mortality, respectively, between blacks and 
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The authors reply: Although we are aware of 
the data cited by Lowenfels et al., we believe they 
must be kept in proper context. The incidence of 
colorectal cancer is rising in the population 
younger than 50 years of age, but the absolute 
increase is small: approximately 2 cases per 
100,000 persons. The corresponding decrease in 
the population 50 years of age or older, by contrast, 
is approximately 100 cases per 100,000 persons.1 
Despite these opposing trends, the incidence of 
colon cancer remains 15 times as high in the 
older group as in the younger group. Given the 
low absolute risk and stable mortality among 
young people, as well as the fact that their dis-
ease may have distinct biologic factors2 that make 
it less amenable to early detection, we believe it 
would be a mistake to extend screening on the 
basis of these trends.
We are also aware of the microsimulation 
modeling cited by Matuchansky. We worry, as 
others do,3 that although the output of statistical 
models have the appeal of quantitative precision, 
their precision may be more apparent than real. 
Modeling is only as good as its data inputs and 
often rests on unverifiable assumptions regard-
ing factors such as the rates at which polyps 
transition to cancer and at which cancers transi-
tion from early to later stages.
The suggestion that 53% of the decline is due 
to screening overstates the precision of the esti-
mate. We believe that it also overstates the mag-
nitude of the likely effect of screening. As the 
figure in our article shows, since 1975, colorectal-
cancer–related mortality has fallen from approxi-
mately 100 cases per 100,000 persons to 45 cases 
per 100,000, and 80% of that decline occurred 
before 2005 — the first year that 50% of the 
population was screened. How can more than 
half the decline in mortality be attributed to 
screening when more than half the decline 
 occurred before even half the population was 
exposed to screening?
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